Meeting
2016 Gastrointestinal Cancers Symposium
Phase III double-blinded, placebo-controlled study of MABp1 for improving survival in metastatic colorectal cancer.
Authors
Sanjay Goel
Montefiore Einstein Cancer Center, Bronx, NY
Sanjay Goel , Lucjan Wyrwicz , Minsig Choi , Andrew L. Coveler , Antonio Ucar , Alexander Ward Brown , Tomasz Sarosiek , Lucas Wong , Michael Stecher , George A. Fisher , Andrew Eugene Hendifar
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT01767857
Citation
J Clin Oncol 34, 2016 (suppl 4S; abstr TPS784)
DOI
10.1200/jco.2016.34.4_suppl.tps784
Abstract #
TPS784
Poster Bd #
O15
Abstract Disclosures
Similar Posters
Poster
2021 Gastrointestinal Cancers Symposium
FRESCO-2: A global phase III study of the efficacy and safety of fruquintinib in patients (pts) with metastatic colorectal cancer (mCRC).
First Author: Arvind Dasari
Poster
2019 ASCO Annual Meeting
BRCA1 genetic variant to predict survival in metastatic colorectal cancer (mCRC) patients (pts) treated with FOLFIRI/bevacizumab (bev): Results from phase III TRIBE and FIRE-3 trials.
First Author: Madiha Naseem
Poster
2022 ASCO Gastrointestinal Cancers Symposium
BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cet) ± chemotherapy for first-line treatment (tx) of BRAF V600E-mutant (BRAFV600) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Trajectories of body weight change and survival among mCRC patients treated with systemic therapy: Pooled analysis from the ARCAD database.
First Author: Jan Franko